« Return to News | Drug Sponsors

Bayer to cut 540 jobs

Friday, May 27, 2011 12:23 PM

Bayer HealthCare is ending production of its multiple sclerosis drug Betaseron in Emeryville, Calif. and taking it to Germany, according to Fierce Pharma. The production move will cut about 540 jobs.  Betaseron will be produced under a contract with Boehringer Ingelheim.

"We are really proud of the employees here in Emeryville and what they've done," said Catherine Anderson, a spokeswoman for Bayer HealthCare, according to the Contra Costa Times. "It has nothing to do with site performance, but rather about Bayer trying to get greater flexibility in this marketplace."

A Bayer spokesman pointed out that the drugmaker operates another manufacturing facility in Berkeley that is undergoing a $100 million upgrade to make the company's new hemophilia therapy, a local station reported. Employees at the Emeryville facility will have the opportunity to apply for jobs at the Berkeley plant.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.